Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Seagen Inc (SGEN)
Seagen Inc (SGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,634,528
  • Shares Outstanding, K 187,504
  • Annual Sales, $ 1,962 M
  • Annual Income, $ -610,310 K
  • 60-Month Beta 0.53
  • Price/Sales 18.60
  • Price/Cash Flow N/A
  • Price/Book 13.40
Trade SGEN with:

Options Overview Details

View History
  • Implied Volatility 23.81% ( +0.44%)
  • Historical Volatility 21.39%
  • IV Percentile 22%
  • IV Rank 23.79%
  • IV High 74.87% on 06/06/22
  • IV Low 7.88% on 03/29/23
  • Put/Call Vol Ratio 0.06
  • Today's Volume 553
  • Volume Avg (30-Day) 10,839
  • Put/Call OI Ratio 1.91
  • Today's Open Interest 250,120
  • Open Int (30-Day) 178,118

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.78
  • Number of Estimates 11
  • High Estimate -0.64
  • Low Estimate -0.93
  • Prior Year -0.73
  • Growth Rate Est. (year over year) -6.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
184.69 +5.79%
on 05/16/23
201.00 -2.80%
on 05/11/23
-4.55 (-2.28%)
since 05/02/23
3-Month
169.13 +15.52%
on 03/10/23
207.16 -5.69%
on 04/13/23
+16.71 (+9.35%)
since 03/02/23
52-Week
116.08 +68.31%
on 12/06/22
207.16 -5.69%
on 04/13/23
+60.18 (+44.51%)
since 06/02/22

Most Recent Stories

More News
3 Stocks Worth Buying at 52-Week Lows

Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors

KDP : 31.45 (+0.90%)
MNST : 59.48 (+0.20%)
PFE : 38.36 (+0.89%)
SGEN : 195.38 (+0.36%)
AMGN : 218.07 (+1.77%)
HZNP : 99.93 (-0.47%)
CVS : 69.99 (+1.61%)
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?

Should Pfizer and Seagen investors be worried?

HZNP : 99.93 (-0.47%)
AMGN : 218.07 (+1.77%)
PFE : 38.36 (+0.89%)
SGEN : 195.38 (+0.36%)
Buy, Sell, or Hold: Pfizer Inc. (PFE)

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out… ...

IRWD : 11.03 (+1.38%)
NVO : 157.14 (-0.53%)
NVS : 98.91 (+1.85%)
PFE : 38.36 (+0.89%)
SGEN : 195.38 (+0.36%)
Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News

The pharmaceutical giant wouldn't be borrowing if it didn't have plans for how to make a tidy return.

PFE : 38.36 (+0.89%)
SGEN : 195.38 (+0.36%)
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?

Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal.

PFE : 38.36 (+0.89%)
SGEN : 195.38 (+0.36%)
AMGN : 218.07 (+1.77%)
HZNP : 99.93 (-0.47%)
Stocks Undercut as Little Progress is seen in U.S. Debt Ceiling Talks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.63%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.01%, and the Nasdaq 100 Index ($IU ) (QQQ ) closed up...

$SPX : 4,282.37 (+1.45%)
SPY : 427.92 (+1.45%)
$DOWI : 33,762.76 (+2.12%)
DIA : 338.07 (+2.15%)
$IUXX : 14,546.64 (+0.73%)
QQQ : 354.65 (+0.75%)
HD : 295.94 (+2.62%)
CZR : 44.86 (+7.68%)
ETSY : 85.01 (+3.68%)
MHK : 96.68 (+4.61%)
WHR : 135.69 (+3.26%)
SGEN : 195.38 (+0.36%)
Stocks Mixed as Debt Ceiling Talks Resume

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.16%. U.S....

$SPX : 4,282.37 (+1.45%)
SPY : 427.92 (+1.45%)
$DOWI : 33,762.76 (+2.12%)
DIA : 338.07 (+2.15%)
$IUXX : 14,546.64 (+0.73%)
QQQ : 354.65 (+0.75%)
HD : 295.94 (+2.62%)
MHK : 96.68 (+4.61%)
MAS : 51.47 (+4.91%)
SWK : 80.73 (+6.03%)
WHR : 135.69 (+3.26%)
SGEN : 195.38 (+0.36%)
This Dividend Stock Is Oversold and Yields 4.3%

Buying an oversold stock can be a good contrarian bet for investors to make, especially if the business' ...

PFE : 38.36 (+0.89%)
SGEN : 195.38 (+0.36%)
Biotech ETFs Pop on M&A Resurgence

2023 could be a year of heightened biotech dealmaking activity

GSK : 34.11 (+0.92%)
NVS : 98.91 (+1.85%)
PFE : 38.36 (+0.89%)
MRK : 112.52 (+1.43%)
AMGN : 218.07 (+1.77%)
GILD : 77.89 (+2.20%)
VRTX : 333.78 (+3.14%)
IBB : 128.98 (+1.74%)
SGEN : 195.38 (+0.36%)
RXDX : 198.83 (+0.09%)
XBI : 86.43 (+1.59%)
SBIO : 32.39 (+1.87%)
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

SGEN : 195.38 (+0.36%)
AZN : 72.59 (-0.34%)
IMGN : 14.37 (+1.41%)
GSK : 34.11 (+0.92%)
GSK.LN : 1,367.600 (+1.48%)
PFE : 38.36 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries....

See More

Key Turning Points

3rd Resistance Point 198.05
2nd Resistance Point 196.97
1st Resistance Point 196.17
Last Price 195.38
1st Support Level 194.29
2nd Support Level 193.21
3rd Support Level 192.41

See More

52-Week High 207.16
Last Price 195.38
Fibonacci 61.8% 172.37
Fibonacci 50% 161.62
Fibonacci 38.2% 150.87
52-Week Low 116.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar